[Cell Metabolism] In a retrospective cohort of patients with B cell acute lymphoblastic leukemia treated with CD22-directed CAR T cells, sustained high-grade fever inversely correlated with clinical response.

[Cell Stem Cell] Researchers identified urokinase plasminogen activator receptor as a shared surface marker on subsets of macrophages and fibro-adipogenic progenitors exhibiting strong pro-inflammatory and fibrogenic signatures in Duchenne muscular dystrophy.

[Nature Medicine] Scientists reported results from a completed first-in-human single-center Phase 1 trial and an ongoing Phase I/II multicenter trial of amsokigene autoleucel, a TIL cell therapy in patients with advanced melanoma progressing after immune checkpoint inhibitor therapy.

[Cell Death & Disease] Investigators explored the therapeutic potential of GD2 CAR T cells in Ewing’s sarcoma, a disease for which effective treatment options remain a significant unmet medical need.

[Expert Reviews in Molecular Medicine] The authors summarize current cell-based therapeutic strategies, their clinical applications, and the key challenges in the context of autoimmune diseases.

[Nature Materials] Researchers developed lipid nanoparticles encapsulating mRNA to reprogram tumour-associated macrophages into CAR macrophages targeting Claudin18.2-positive tumour ascites.

[Nature Genetics] Scientists studied patients with lymphoma receiving CAR19 and compared clinical outcomes to propensity-matched autologous hematopoietic cell transplantation-treated controls. CAR19-treated patients exhibited impaired immune reconstitution and increased infection.

[International Immunology] Scientists summarize the current status of acute myeloid leukemia (AML) therapy, discuss the challenges of identifying suitable CAR targets, and introduces CAR T- and CAR natural killer-cell strategies targeting mismatched HLA-DRB1 molecules for treating relapsed AML after allogeneic hematopoietic cell transplantation.

[Nature Cancer] The authors showed that integrating the spatial precision of ionizing radiation with the biological specificity of CAR-T cells enables localized delivery of the inflammatory cytokine tumor necrosis factor (TNF).

[Elicera Therapeutics ] Elicera Therapeutics announced that the company’s co-founder, Dr. Di Yu, has been awarded a grant from the Swedish Research Council. The four-year research project aims to increase knowledge of how CAR-T cells should be designed to persist longer in the body and more easily penetrate solid tumors.

[Science] Researchers identified a microbial-immune-epithelial feedback mechanism that integrates environmental information into stem cell regulation in mice.

[Annals of the Rheumatic Diseases] Scientists investigated the role of nicotinamide N-methyltransferase in dermal fibroblast activation and fibrosis in systemic sclerosis.